LXRX · Lexicon Pharmaceuticals, Inc. · Documents

$1.79 -0.03 (-1.65%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$796.97M

445.23M

Volume · Nov 13 1.89M Avg daily vol (3M) 2.62M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $49.8M up 60.2% 10-K filed Mar 5, 2026 Quarterly report FY2026 Q3 Revenue $11.25M down 20.7% 10-Q filed Nov 5, 2026 Latest results SONATA-HCM substantially overenrolled with 542 patients 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026

2026

Nov 5

Earnings call

Sonata results and Zenquista NDA resubmission expected in 2027

Lexicon completed enrollment in the 542-patient Phase 3 Sonata HCM trial, with top-line results expected in the first quarter of 2027, and plans to resubmit the Zenquista NDA for type 1 diabetes in the same quarter.

6 source passages

Welcome to the Lexicon Pharmaceuticals' third quarter, 2026 Financial Results Conference Call. First and foremost, in HCM, we completed patient enrollment in our Phase 3 Sonata HCM study. In total, Sonata HCM enrolled 542 patients with 440 classified as non-obstructive at baseline And 102 is obstructive. We're very pleased with the overall enrollment profile of Sonata HCM and look forward to reporting top line results in the first quarter of 2027. Now, moving to Zenquista, we continue to make strong progress towards the resubmission of our NDA and type 1 diabetes, supported by new prospective safety data from the investigator-initiated STENO1 study. While this process is taking longer than we originally anticipated, we expect to complete the resubmission in the first quarter of 2027. Open the document at this passage

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Revenue falls as nine-month net loss widens to $46.8 million

Lexicon Pharmaceuticals reported revenues of $33.0 million for the nine months ended September 30, 2026, down from $44.3 million, while net loss widened to $46.8 million from $34.8 million. Cash, cash equivalents, short-term investments and restricted cash totaled $183.2 million.

Revenue $11.25M ▼ 20.7% Net loss $14.01M Diluted EPS -$0.03

Read from the MD&A section

3 source passages

Revenues were $11.3 million and $14.2 million, respectively, for the three months ended September 30, 2026 and 2025 and $33.0 million and $44.3 million, respectively, for the nine months ended September 30, 2026 and 2025. Net loss was $46.8 million, or $0.11 per share, in the nine months ended September 30, 2026 as compared to a net loss of $34.8 million, or $0.10 per share, in the corresponding period in 2025. As of September 30, 2026 and December 31, 2025, total cash, cash equivalents, short-term investments and restricted cash were $183.2 million and $125.2 million, respectively. Open the document at this passage

Nov 5

Current report 8-K

SONATA-HCM substantially overenrolled with 542 patients

Lexicon Pharmaceuticals, Inc. completed SONATA-HCM enrollment with 542 patients, substantially exceeding planned enrollment, and expects topline results in the first quarter of 2027; ZYNQUISTA NDA resubmission is also anticipated in the first quarter of 2027.

Financial results

5 source passages

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today reported financial results for the three months ended September 30, 2026, and provided an update on key corporate milestones and accomplishments. Enrollment has been completed in SONATA-HCM, a pivotal Phase 3 placebo-controlled study in patients with symptomatic obstructive (oHCM) and non-obstructive (nHCM) hypertrophic cardiomyopathy. The trial enrolled a total of 542 patients across both nHCM and oHCM, substantially exceeding its planned enrollment. Lexicon continues to expect topline results in the first quarter of 2027. Lexicon remains focused on bringing ZYNQUISTA to market for glycemic control in adults with T1D, a patient population for which there are no treatment options beyond insulin. Data preparation and administrative work is now being completed to support a high-quality NDA resubmission, anticipated in the first quarter of 2027. Open the document at this passage

Sep 14

Investor event

H.C. Wainwright 28th Annual Global Investment Conference AI summary on its way

Sep 9

Investor event

Citi 2026 Biopharma Back to School Conference AI summary on its way

Aug 6

Earnings call

Q2 2026 earnings call AI summary on its way

Aug 6

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way